Other new investors participating in the financing included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel company), Wellington Management company, and an undisclosed leading global investment firm.
Existing investors, 5AM Ventures, RA Capital Management, and venBio Partners, along with strategic partners GC LabCell (Green Cross LabCell Corp., KRX: 14451) and GC (Green Cross Holdings Corp., KRX:005250), also participated in the financing.
Artiva plans to use the proceeds from the financing to advance its NK cell therapy development programs and expand ongoing research and development activities.
Artiva's cell therapies are designed to leverage the innate anti-tumor biology and safety features of NK cells.
The therapies are optimized for targeted anti-cancer activity through CARs, or ADCC enhancement through therapeutic antibody or innate-cell engager combination therapy.
Artiva's manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies, and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity.
Artiva's mission is to deliver to cancer patients highly effective cellular immunotherapies that are safe and immediately accessible.
Artiva's pipeline includes AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers.
The company is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.
The company's CAR-NK programs include AB-201, a novel HER2-specific CAR-NK cell therapy for the treatment of HER2+ solid tumors, and AB-202, a CD19-specific CAR-NK cell therapy for the treatment of B-cell malignancies, which are being developed under Artiva's master license and option agreement with GC LabCell Corp., with plans to enter clinical trials in 2022.
The company has entered into therapeutic NK cell collaborations and/or license agreements with Merck and with Affimed N.V.
Artiva's NK cell platform incorporates cell expansion, activation, and engineering technology developed by the company's corporate partner, GC LabCell, a member of the GC family of companies, one of the Republic of Korea's leading biopharmaceutical groups. Artiva is headquartered in San Diego.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval